GAO Examines Impact Of DME Comp Bidding Pricing Extension To Non-CBAs

Recently, the GAO released an analysis of CMS’ move in 2016 to set DME rates in areas not subject to DME competitive bidding based on competitively bid rates from other areas.   The GAO found the results in those areas largely mirrored the results from competitive bidding nationwide: significant rate cuts and more consolidation of suppliers, while utilization remained flat overall - though some items went up or down significantly. As CMS is currently considering restructuring the DME program, this data is particularly timely. Click to read more.

Managed Care Friday

1. 45: Dr Karens felt a bit like Larry David did during that classic Curb Your Enthusiasm scene when a woman got called in to see the doctor before Larry, only because she signed in first, even though Larry’s appointment was earlier. ‘I call Shenanigans!’ Larry argued. Dr. Karens, a pediatrician at a busy practice in the northeast I’ve known for about a decade, told me this week that she had to cancel our monthly chat because she lost her two best NPs to the local hospital and was knee deep in patient visits for sniffles and ‘the angry mob of helicopter moms’ whose children’s ‘red finger...

Stark And Anti-Kickback Debates Heat Up As Summer Ends

For years, physicians have had to be mindful of two major Medicare restrictions: the so-called “Stark law” which limits physician self-referral and the anti-kickback statute which prohibits physicians from receiving remuneration for referrals. While those have been basic compliance cornerstones of the fee-for-service Medicare world, both are now being questioned by CMS and the OIG as new payment models come online. Click to read more.
Part D Premiums Decline While Government Spending Climbs

Part D Premiums Decline While Government Spending Climbs

Since implementation in 2006, the Medicare Part D program has been relatively stable, popular with beneficiaries, and seen relatively few structural changes.  Recently, CMS announced that for the second year in a row, basic Part D premiums are actually expected to decline.  However, there are several trends below the hood which are raising concerns and may lead to reforms in the not too distant future. Click to read more.

Measuring the Relative Size of the 340B Program: 2017 Update

The 340B Drug Discount Program has come under increased scrutiny in recent years from government agencies and others who note the negative impact the program may have on the broader market for pharmaceuticals. This impact is in part due to the program’s increasing size relative to the overall pharmaceutical market. Since 2010, the program has expanded at an average annual growth rate of 21 percent and has grown by 114 percent in the last three years alone. In May 2018, the Health Resources and Services Administration (HRSA) reported that in 2017, 340B covered entities purchased more than $19...